Your basket is currently empty!
ASPEN Compares Sunitinib, Everolimus in Metastatic Non-Clear Cell Renal Cell Carcinoma
Clinicians now have a better picture of what may be the optimal first-line therapy for patients with metastatic non-clear cell renal cell carcinoma (NC-RCC), according to results from a randomized phase 2 international trial of everolimus compared with sunitinib.
Investigators reported at the 2015 American Society of Clinical Oncology Annual Meeting that sunitinib was superior overall compared with everolimus at delaying disease progression. However, it was also associated with a higher rate of severe toxicity.1
The researchers found that sunitinib was more effective for papillary-type kidney cancers and for better prognosis patients.
Patients with chromophobe and poor-risk tumors treated with everolimus had a longer median progression-free survival (PFS) than patients treated with sunitinib.
“We wanted to know which was better. We don’t a have a standard of care,” said lead study author Andrew Armstrong, MD, who is the co-director of the Genitourinary Oncology Research Program at Duke Cancer Institute in Raleigh, NC……..read the full story here